Table 2

Immunohistochemistry results
Patients Median percentage of TDLUs containing ALDH+ cells (range)
Luminal ductular level Intermediate ductular level Basal ductular level
Pre-menopausal with family history of breast cancer, including patients with BRCA1 or BRCA2 mutation (n = 37) 12 (0–62)** 12 (0–53)** 2 (0–18)
Pre-menopausal with BRCA1 mutation (n = 18) 15 (2–50)* 15 (6–38)* 4 (0–18)
Pre-menopausal with BRCA2 mutation (n = 13) 14 (0–62)* 8 (2–53)* 0 (0–18)
Pre-menopausal without family history of breast cancer (n = 25) 6 (0–29) 6 (0–44) 0 (0–29)
Post-menopausal receiving HRT at the time of surgery (n = 7) 10 (0–38)* 8 (0–38)* 2 (0–21)
Post-menopausal not receiving HRT at the time of surgery (n = 24) 4 (0–32) 4 (0–34) 0 (0–18)
Nocancer, underwent mammoplasty (n = 34) 6 (0–32) 4 (0–44) 0 (0–29)

A statistical comparison of ALDH immunohistochemistry results for patients with and without a family history of breast cancer, and patients who were or were not receiving HRT at the time of surgery.

*P ≤ 0.05.

**P ≤ 0.01.

ALDH, aldehyde dehydrogenase 1 A1; TDLU, terminal duct lobular unit; HRT, hormone replacement therapy.

Isfoss et al.

Isfoss et al. BMC Clinical Pathology 2013 13:28   doi:10.1186/1472-6890-13-28

Open Data